Resource Summary Report

Generated by NIF on Apr 9, 2025

MuTect

RRID:SCR_000559
Type: Tool

Proper Citation

MuTect (RRID:SCR_000559)

Resource Information

URL: http://www.broadinstitute.org/cancer/cga/mutect

Proper Citation: MuTect (RRID:SCR_000559)

Description: Software for the reliable and accurate identification of somatic point mutations in next generation sequencing data of cancer genomes.

Abbreviations: MuTect

Synonyms: Mutect

Resource Type: software resource

Defining Citation: PMID:23396013

Keywords: next-generation sequencing, somatic mutation, tumor, normal, genome, bio.tools

Related Condition: Cancer

Funding:

Availability: Free for academic use, Non-commercial, Commercial use requires commercial license, Account required

Resource Name: MuTect

Resource ID: SCR_000559

Alternate IDs: biotools:mutect, OMICS_00087

Alternate URLs: https://bio.tools/mutect

Record Creation Time: 20220129T080202+0000

Record Last Update: 20250214T182916+0000

Ratings and Alerts

No rating or validation information has been found for MuTect.

No alerts have been found for MuTect.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 74 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF.

Sun X, et al. (2025) Targeting PRMT1 Reduces Cancer Persistence and Tumor Relapse in EGFR- and KRAS-Mutant Lung Cancer. Cancer research communications, 5(1), 119.

Liu M, et al. (2024) Unveiling the metal mutation nexus: Exploring the genomic impacts of heavy metal exposure in lung adenocarcinoma and colorectal cancer. Journal of hazardous materials, 461, 132590.

Sun Y, et al. (2024) Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. Cancer cell, 42(1), 135.

Iida N, et al. (2024) Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(18), 4167.

Kebede AM, et al. (2024) Comprehensive genomic characterization of hematologic malignancies at a pediatric tertiary care center. Frontiers in oncology, 14, 1498409.

De Bellis C, et al. (2024) Genomic, epigenomic and transcriptomic inter- and intra-tumor heterogeneity in desmoid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research.

Hariprakash JM, et al. (2024) Leveraging Tissue-Specific Enhancer-Target Gene Regulatory Networks Identifies Enhancer Somatic Mutations That Functionally Impact Lung Cancer.

Cancer research, 84(1), 133.

Lee EJ, et al. (2024) Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(8), 1582.

Anselmino N, et al. (2024) Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(10), 2272.

Li L, et al. (2024) Comprehensive Proteogenomic Profiling Reveals the Molecular Characteristics of Colorectal Cancer at Distinct Stages of Progression. Cancer research, 84(17), 2888.

Wu L, et al. (2024) Tumour microenvironment programming by an RNA-RNA-binding protein complex creates a druggable vulnerability in IDH-wild-type glioblastoma. Nature cell biology, 26(6), 1003.

Krull JE, et al. (2024) Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments. Cell reports. Medicine, 5(3), 101443.

Johanns TM, et al. (2024) Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(13), 2729.

Ceresa D, et al. (2023) Early clonal extinction in glioblastoma progression revealed by genetic barcoding. Cancer cell, 41(8), 1466.

Lheureux S, et al. (2023) Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(18), 3706.

van den Bulk J, et al. (2023) Neoantigen Targetability in Progressive Advanced Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(20), 4278.

Bhinder B, et al. (2023) Immunogenomic Landscape of Neuroendocrine Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(15), 2933.

Thummalapalli R, et al. (2023) Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(21), 4408.

Senkowski W, et al. (2023) A platform for efficient establishment and drug-response profiling

of high-grade serous ovarian cancer organoids. Developmental cell, 58(12), 1106.

Wu T, et al. (2022) Quantification of Neoantigen-Mediated Immunoediting in Cancer Evolution. Cancer research, 82(12), 2226.